Canada - English - Health Canada

mint pharmaceuticals inc - lacosamide - tablet - 200mg - lacosamide 200mg - miscellaneous anticonvulsants

Canada - English - Health Canada

angita pharma inc. - lacosamide - tablet - 50mg - lacosamide 50mg - miscellaneous anticonvulsants

Canada - English - Health Canada

angita pharma inc. - lacosamide - tablet - 100mg - lacosamide 100mg - miscellaneous anticonvulsants

Canada - English - Health Canada

angita pharma inc. - lacosamide - tablet - 150mg - lacosamide 150mg - miscellaneous anticonvulsants

Canada - English - Health Canada

angita pharma inc. - lacosamide - tablet - 200mg - lacosamide 200mg - miscellaneous anticonvulsants

Canada - English - Health Canada

sanis health inc - lacosamide - tablet - 50mg - lacosamide 50mg - miscellaneous anticonvulsants

Canada - English - Health Canada

sanis health inc - lacosamide - tablet - 100mg - lacosamide 100mg - miscellaneous anticonvulsants

Canada - English - Health Canada

sanis health inc - lacosamide - tablet - 150mg - lacosamide 150mg - miscellaneous anticonvulsants

Canada - English - Health Canada

sanis health inc - lacosamide - tablet - 200mg - lacosamide 200mg - miscellaneous anticonvulsants

United States - English - NLM (National Library of Medicine)

ucb, inc. - lacosamide (unii: 563ks2pqy5) (lacosamide - unii:563ks2pqy5) - lacosamide 50 mg - vimpat is indicated for the treatment of partial-onset seizures in patients 1 month of age and older. vimpat is indicated as adjunctive therapy in the treatment of primary generalized tonic-clonic seizures in patients 4 years of age and older. none. pregnancy exposure registry there is a pregnancy exposure registry that monitors pregnancy outcomes in women exposed to antiepileptic drugs (aeds), such as vimpat, during pregnancy. encourage women who are taking vimpat during pregnancy to enroll in the north american antiepileptic drug (naaed) pregnancy registry by calling 1-888-233-2334 or visiting http://www.aedpregnancyregistry.org/. risk summary available data from the north american antiepileptic drug (naaed) pregnancy registry, a prospective cohort study, case reports, and a case series with vimpat use in pregnant women are insufficient to identify a drug-associated risk of major birth defects, miscarriage or other adverse maternal or fetal outcomes. lacosamide produced developmental toxicity (increased em